To determine the clinical safety and efficacy of preoperative glucocorticoid (GC) administration in major abdominal surgery with regards to short term outcomes. Background: Previous randomized controlled trials (RCTs) in major abdominal surgery have displayed conflicting results regarding the short-term benefits of preoperative GC administration. Importantly, the safety of this intervention has not been conclusively determined. Methods: A systematic review and quantitative meta-analysis was conducted of all RCTs exploring preoperative GC administration in major abdominal surgery for the endpoints of complications, hospital length of stay (LOS) and serum IL-6 on postoperative day one. Subset analyses by procedure were planned "a priori." Results: Eleven RCTs of moderate quality, comprising 439 patients in total, were included in the final analysis. Preoperative GC use decreased complications (OR = 0.37; 95% CI, 0.21-0.64; P < 0.01), LOS (mean = 1.97 days; 95% CI, -3.33 to -0.61; P = 0.01), and serum IL-6 (mean: -55 pg/mL; 95% CI, -82.30 to -27.91; P < 0.01). Preoperative GCs decreased complications in hepatic resection (OR = 0.28; 95% CI, 0.14-0.55; P < 0.01) and mean LOS (mean LOS: -2.66; 95% CI, -5.01 to -0.32; P = 0.03). GCs reduced mean LOS in patients undergoing colorectal surgery (mean LOS: -0.98; 95% CI, -1.67 to -0.27; P = 0.01). There was no difference in complication rates (OR: 0.45; 95% CI, 0.16-1.32; P = 0.15) or anastomotic leaks specifically. Conclusions: Preoperative administration of GCs decreases complications and LOS after major abdominal surgery as a likely consequence of attenuating the postsurgical inflammatory response. There is no evidence of increased complications in colorectal surgery. (Ann Surg 2011;254:183-191) 
Glucocorticoids (GCs) have been postulated as a suitable pretreatment agent to attenuate the postsurgical stress response. 10 Although their molecular mechanisms have not been completely elucidated, they can modify the surgically induced neurohumoral mediators of injury and inflammation. 11 Within experimental models, GCs have been shown to decrease proinflammatory cytokines such as IL-6, IL-1, and TNF-α. 12 GCs also have an antipyretic effect and increase blood glucose concentration and leucocyte count and may have beneficial effects on postoperative renal function. 10, [13] [14] [15] GCs have found many clinical indications and have been extensively investigated in the context of treatment for sepsis, where prolonged use in low doses has been thought to provide a survival advantage. 16 Within surgical settings, the use of GCs has been evaluated in cardiac surgery where they have been shown to mitigate against ischemia-reperfusion injury. [17] [18] [19] They have been shown to decrease nausea and vomiting after laparoscopic cholecystectomy. 20 GCs have also been used for immunosuppression in liver transplantation and may improve postoperative outcomes. 13, [21] [22] [23] However, their safety and efficacy has not been established in major elective abdominal surgery with concerns regarding potential increases in infectious complications. 10 Moreover, GCs cause hyperglycaemia which is now known to be associated with an exaggerated catabolic response and increased complications. 24, 25 Previously published trials have been powered for indices of efficacy with conflicting results and importantly, have not been powered to detect adverse outcomes as the large numbers of patients required can make this logistically challenging. 26, 27 As a result, a systematic review and meta-analysis of all randomized controlled trials (RCTs) exploring pretreatment with GCs in major elective abdominal surgery was conducted to determine both safety and efficacy.
METHODS

Systematic Literature Search
The search terms used are as per Table 1 and these were combined with the Cochrane Highly Sensitive Search Strategy for identifying RCTs. 28 The search was run independently by 2 authors (S.S. and T.C.Y.) according to the validated methods of the PRISMA statement. 29 There were no restrictions on language. The databases examined were MEDLINE (1966-2010), Cochrane Central Register of Controlled Trials, EMBASE (1947-2010) and PubMed. A third author (AAK) conducted a search of relevant scientific meeting abstracts and international trial registers to identify unpublished studies. The reference lists of all included papers and related review articles, were manually searched to identify further relevant studies. All studies up to and including June 2010 were eligible for inclusion. 
Data Abstraction
The chief outcomes of interest were total complications, hospital length of stay (LOS) and serum IL-6 on postoperative day one. This time-point was chosen as it corresponds to the peak levels of IL-6 after abdominal surgery. 30 These were gathered where available and summarized on an intention to treat basis in predesigned tables. Complications were counted as per event and were assumed as defined if published. Corresponding authors were contacted in the event of missing information. In the event of no response for 2 weeks, the authors were contacted again. If there was no response in the subsequent 2 weeks (1 month total), the study was excluded for the endpoint of interest but included for all other endpoints where information was available. A subset analysis by specialty was planned a priori for the major outcomes of complications and LOS. A subset analysis was also planned for anastomotic leaks in colorectal surgery. A separate subset analysis was also conducted for the endpoint of infectious complications. Only statistically significant findings shown in "Results" section. Endpoints not mentioned in "Results" section showed nonsignificant (P <0.05) findings. N indicates sample size; ↑, Increased/Improved; ↓, Decreased; =, No difference; -, Not Stated; MP, methylprednisolone; IL, interleukin; CRP, C-reactive protein; DTH, delayed type hypersensitivity; #, duplicate publications; PGE2, prostaglandin E2; Cx, complications; FEV, forced expiratory volume; FVC, forced vital capacity; LOS, length of stay; T-bil, total bilirubin; AST, asparginate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; IAP, immunosuppressive acidic protein; Cr, creatinine; AT-III, antithrombin III; HLA-DR, human leucocyte antigen-DR; WBC, white blood cell. administration on anastomotic leaks in colorectal surgery was examined using the PETO odds ratio method as anastomotic leaks were anticipated to be rare events. 21 Medians were converted to means using the technique described by Hozo et al. 31 Forest plots were then constructed with P < 0.05 considered statistically significant. Statistical heterogeneity was evaluated using I 2 statistics and a χ 2 test for heterogeneity was performed, with P < 0.1 regarded as statistically significant. 28 An I 2 value of less than 25% was defined to represent low heterogeneity, a value between 25% to 50% was defined as moderate heterogeneity and a value of greater than 50% was defined as high heterogeneity. 28 Funnel plots were used to screen for publication bias.
RESULTS
Trial Flow
The literature search identified 1332 records, which were refined to 954 abstracts. The full text was analyzed for 154 papers and 11 RCTs, spanning over 14 publications, were included. 13, 26, 27, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] A PRISMA statement is shown in Figure 1 were noted in most RCTs with authors providing data regarding serum IL-6 levels and further clarification regarding outcomes where necessary. The authors of 9 of the trials were contacted. 13, 26, 32, 35, [38] [39] [40] [41] [42] Eight authors replied and 6 were able to provide the requested information.
Study Characteristics
The study characteristics are as per Table 2 . None of the trials were stopped early due to adverse events or for any other reason. Six trials reported a power calculation. 13, 26, 34, 36, 38, 42 Most trials explicitly defined 13, 27, 32, [35] [36] [37] 39, 41 and measured complications until 30 days postoperatively. 26, 27, 39, 42 Overall, this meta-analysis included 217 patients randomized to GCs and 222 patients in the control group. The risk of bias summary and funnel plot are as per Figures 2 and 3 , respectively. The studies were generally of moderate quality with minimal publication bias.
Outcomes
Preoperative GC use was associated with significantly decreased complications (OR = 0.37; 95% CI, 0.21-0.64; P < 0.01) with minimal heterogeneity in the results (I 2 = 22%; P = 0.23) as shown in Figure 4 . GC use also decreased infectious complications specifically (OR = 0.35; 95% CI, 0.18-0.67; P < 0.01) with nil heterogeneity (I 2 = 0%, P = 0.68) as shown in Figure 5 . GC use decreased mean LOS by 2.0 days (95% CI, -3.33 to -0.61; P = 0.01) with high levels of heterogeneity (I 2 = 66%; P< 0.01) as per Figure 6 . GCs also decreased serum IL-6 on postoperative day one by a mean of 55 pg/mL (95% CI, -82.30 to -27.91; P < 0.01) with high heterogeneity in the results (I 2 = 90%; P < 0.01) as shown in Figure 7 .
Subset Analyses
Preoperative GCs decreased complications in hepatic resection (OR = 0.28; 95% CI, 0.14-0.55; P < 0.01) with minimal heterogeneity in the results (I 2 = 11%; P = 0.35) as per Figure 8 . Mean LOS was decreased in this subset (mean LOS, -2.66; 95% CI, -5.01 to -0.32; P = 0.03) and the studies were of high heterogeneity ((I 2 = 54%; P = 0.07) as shown in Figure 9 .
Preoperative GCs tended to reduce complications in colorectal surgery though these results were not statistically significant (OR, 0.45; 95% CI, 0.16-1.32; P = 0.15) and studies were of moderate heterogeneity (I 2 = 42%; P = 0.16) as shown in Figure 10 . There was no difference in anastomotic leaks between the 2 groups as shown in Figure 11 . GCs reduced mean LOS in patients undergoing colorectal surgery (mean LOS, -0.98; 95% CI, -1.67 to -0.27; P = 0.01) with nil heterogeneity in the results (I 2 = 0%; P = 0.77) as per Figure 12 .
DISCUSSION
This meta-analysis has shown that preoperative GCs decrease complications-including infectious complications specifically and LOS after major abdominal surgery. This is associated with an attenuation of the postsurgical inflammatory response as evidenced by a decreased concentration of serum IL-6 in patients receiving GCs. These results hold largely true in procedure-specific analyses and in particular, GCs do not seem to increase the risk of complications in colorectal surgery.
The metabolic response to major abdominal surgery is mediated in part by pro-inflammatory cytokine release. 1, 43 Although inflammation is a necessary precursor for healing, it is the excessive amplitude of the inflammatory response after major abdominal surgery that is thought to contribute to postoperative morbidity and delay recovery. 1, 4, 43 Moreover, due to positive-feedback cycles and inherent biological redundancy in the cytokine cascade after the abdominal incision, preoperative treatment with GCs has been postulated as an ideal empirical solution. 10 Previous studies have also demonstrated the superiority of preoperative administration of GCs to obtain antiemetic effects as compared with postoperative administration. 44 Therefore preoperative GCs potentially modulate the balance between proinflammatory and antiinflammatory mediators in the postoperative setting, as shown by a decrease in the proinflammatory cytokine IL-6, with associated benefits for patients.
Previously published reviews have confirmed the efficacy of GCs in reducing postoperative nausea and vomiting. 45 Sauerland et al subsequently reported that GCs were not associated with an increased rate of adverse events whereas Holte et al conducted a comprehensive narrative review on GC use in surgery. 10, 46 A recent meta-analysis exploring GC treatment in oesophageal surgery also demonstrated clinical benefits though the results were limited by the quality of the included studies. 47 However, until now, the safety and efficacy of GCs has not been demonstrated specifically in major abdominal surgery. This meta-analysis shows not only noninferiority in shortterm outcomes, but also demonstrates clinical benefits from GC usage including reduction of infectious complications.
These results are especially impressive as the values obtained are clinically significant and in the case of colorectal surgery, have been obtained within an already optimized environment. Three of the 4 trials within colorectal surgery have incorporated either laparoscopy or Enhanced Recovery After Surgery programs. 26, 27, 42 Though the implementation of Enhanced Recovery pathways has been recognized as being challenging and there are often sociocultural factors influencing postoperative care and hospital LOS in particular, patients in the individual RCTs were managed in the same perioperative environment and therefore any differences seen within the trials can be ascribed to GC use. 48 Moreover, as an intervention, administration of GCs is inexpensive and simple allowing for clinical implementation without difficulty.
The limitations of this meta-analysis include its generalizability due to the exclusion criteria of some of the included trials such as presence of endocrine or cardiopulmonary disease and American Society of Anaesthesiologist (ASA) score greater than 3. 26, 39 Moreover, this study combines the results of trials administering different GCs (eg, methylprednisolone, dexamethasone), which were often administered at different periods in the preoperative setting. Some authors have proposed that GCs should be administered 90 minutes preoper-atively to obtain clinical benefits. 10 Although most of the trials have defined complications, a common system has not been used. A validated scale incorporating the severity of complications such as the Clavien-Dindo classification of surgical complications should ideally be used in future studies. 26, 49, 50 LOS data were not available for 2 trials, though the study by Turner et al also reported trends in LOS favoring GCs. 13, 39 Because of the small number of patients, the influence of GCs on anastomotic leaks in colorectal surgery cannot be definitively stated and future studies should prospectively record these data. Importantly, whereas GCs have improved short-term outcomes, their influence on oncological outcomes is as yet unknown. Perioperative immunosuppression has been postulated to have adverse effects on oncological outcomes in colorectal cancer whereas a single dose of GC has been shown to promote metastasis in murine models. 51, 52 Similarly, the influence of GC administration on liver regeneration has not been conclusively determined though previous work has demonstrated that excessive production of IL-6 inhibits liver regeneration and thus GCs may potentially be beneficial in this regard. 53, 54 Future studies should evaluate these endpoints while perhaps also examining adhesion-related complications or a suitable proxy such as tissue-plasminogen activator levels in plasma or peritoneal fluid. 55, 56 Because peritoneal cytokine release has been identified as a major contributor to the postsurgical inflammatory response, 5 the use of intraperitoneal GC administration is an intriguing concept. The use of GCs in sepsis has been extensively studied especially with regards to attenuating the procoagulant state in sepsis and a large meta-analysis indicates that prolonged low dose therapy may provide some benefit. 16, 57 Because 2 of the included trials have shown benefits in maintaining coagulation homeostasis and GCs have been shown to specifically decrease postoperative infectious complications, the role of GCs in this context potentially warrants further investigation. 32, 41 This meta-analysis has demonstrated that preoperative treatment with GCs improves short-term outcomes after major abdominal surgery as a likely consequence of attenuating the postsurgical inflammatory response. This should be considered as a routine measure in suitable patients while evaluating long-term outcomes prospectively.
